

## COMPOUND GUIDE

## CJC-1295 with DAC — Long-Acting GHRH Analogue

30-AA GHRH analogue · Drug Affinity Complex · Once-weekly SubQ

## Quick Start



## CJC-1295 DAC VS CJC-1295 NO DAC — CRITICAL DISTINCTION

CJC-1295 with DAC (this guide) has a plasma half-life of 5.8–8.1 days and is dosed once weekly. CJC-1295 without DAC ("Modified GRF 1-29") has a half-life of ~30 minutes and is dosed daily, usually alongside Ipamorelin. These are different protocols and cannot be substituted. Always confirm which version you are working with.



## WHAT IT IS

CJC-1295 with DAC is a 30-amino acid GHRH (Growth Hormone Releasing Hormone) analogue developed by ConjuChem. The Drug Affinity Complex (DAC) technology covalently binds the peptide to serum albumin after injection, dramatically extending its half-life from ~30 minutes to 5.8–8.1 days.



## RESEARCH DOSING

**500–2,000 mcg SubQ once weekly.** Some protocols split into two 500 mcg–1 mg doses twice weekly. No fasting requirement (unlike Ipamorelin). Most research uses 1,000 mcg (1 mg) once weekly for 8–12 weeks.



## REGULATORY STATUS

Not FDA-approved. Phase 2 HIV lipodystrophy trial (NCT00267527) was halted in 2006 following a participant cardiovascular death. FDA Category 2 review record exists; no active trials as of 2026. WADA banned (S2). For research purposes only.



## Dosing Protocol

Dosing figures are not provided for compounds we do not stock.



## Supplies &amp; Reconstitution

## Reconstitution &amp; Dosing

LA LAB does not stock this as a standalone product, so vial-specific reconstitution and dosing figures are not provided here. This page is a research reference only. For compounds we carry, see [our guides](#).

## Vial Planning Guide

| DOSE    | FREQUENCY    | INJECTIONS PER 10 MG VIAL | VIALS FOR 8 WEEKS | VIALS FOR 12 WEEKS |
|---------|--------------|---------------------------|-------------------|--------------------|
| 1 mg    | Once weekly  | 10                        | 1 vial            | 1–2 vials          |
| 2 mg    | Once weekly  | 5                         | 2 vials           | 3 vials            |
| 500 mcg | Twice weekly | 10 (5 weeks)              | 2 vials           | 3 vials            |

## Reconstitution Steps

01

## Warm the vial

Remove from freezer 10–15 min before use. Reach room temperature naturally.

02

## Swab both stoppers

Alcohol swab each vial top. Allow to air-dry before inserting needle.

03

## Draw BAC water

Draw the required BAC water volume (e.g. 3.0 mL for 10 mg vial).

04

## Inject down the wall

Let BAC water run slowly down the inside glass wall of the peptide vial — never jet directly onto the powder.

05

**Gentle swirl**

Swirl slowly until the solution is clear and fully dissolved. Do not shake.

06

**Refrigerate**

Store at 2–8°C, upright, for up to 30 days. Protect from light. Do not freeze after reconstitution.

**Mechanism of Action****GHRH RECEPTOR AGONISM**

Binds pituitary GHRH receptors → cAMP/PKA signalling → GH synthesis and pulsatile release. Mimics endogenous GHRH but with dramatically extended activity due to the DAC modification.

**GH ELEVATION**

Phase 1 human data (Teichman 2006): 2–10× GH elevation sustained for 6+ days after a single injection. Once-weekly dosing maintains elevated baseline GH throughout the cycle.

**DAC TECHNOLOGY**

The Drug Affinity Complex is a maleimidopropionic acid reactive group that covalently binds to serum albumin (Cys-34) after injection. This albumin binding extends half-life to 5.8–8.1 days, allowing once-weekly dosing.

**IGF-1 ELEVATION**

Phase 1 data: IGF-1 elevation 1.5–3× above baseline for 9–11 days after injection. Sustained IGF-1 is the downstream mediator of most studied effects (protein synthesis, body composition).

**Research Status**

| STUDY                 | DESIGN                               | KEY FINDING                                                                       |
|-----------------------|--------------------------------------|-----------------------------------------------------------------------------------|
| Teichman et al. 2006  | Phase 1; healthy adults; single dose | GH 2–10× elevated for 6+ days; IGF-1 1.5–3× for 9–11 days; well tolerated         |
| NCT00267527 (Phase 2) | HIV lipodystrophy; randomised        | Halted 2006 after one participant cardiovascular death; causality not established |

**PHASE 2 TRIAL SAFETY NOTE**

The Phase 2 HIV lipodystrophy trial NCT00267527 was halted in 2006 following a participant cardiovascular death. The investigators noted causality was not established, but development was discontinued. No further Phase 2 or Phase 3 trials have been registered for CJC-1295 with DAC.

**Storage**

| STATE                  | TEMPERATURE          | DURATION        | NOTES                              |
|------------------------|----------------------|-----------------|------------------------------------|
| Lyophilised (powder)   | –20°C (freezer)      | Up to 24 months | Protect from light and moisture    |
| Reconstituted (liquid) | 2–8°C (refrigerator) | Up to 30 days   | Do not freeze after reconstitution |
| Short-term (travel)    | <25°C                | Up to 72 hours  | Avoid heat and direct sunlight     |

**DISCLAIMER**

This document is an educational research reference only. It is not medical advice, not a treatment plan, and not a recommendation to use CJC-1295 with DAC outside of a qualified research context. The Phase 2 trial for this compound was halted following a safety event. WADA banned. By purchasing from LA LAB you confirm you are 18+ and that products are for research purposes only.